Clinical trials: Prostate Intraductal Carcinoma
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Prostate Cancer, Prostate Intraductal Carcinoma
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the…
- Conditions
- Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
- Trial name
- NCT06662708
- Testing
- Accurate Prediction Artificial Intelligence Models
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shao Pengfei
Prostate Cancer
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as…
- Trial name
- SChLAP/IDC (NCT04176081)
- Testing
- Darolutamide, Degarelix, Radiation Therapy
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- University Health Network, Toronto